Coronavirus Update: Moderna Lifted By BARDA funding, Europe Looks For Exit Strategy, Vaccine Funds
Boost For Vaccine Frontrunner
Executive Summary
Plus: Moleculin hopes to move 2-DG prodrug into clinic, India progresses niche COVID-19 defenses and more.
You may also be interested in...
Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals
Company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.
Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.
Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.